Navigation Links
Contrast agent linked with brain abnormalities on MRI
Date:12/16/2013

OAK BROOK, Ill. For the first time, researchers have confirmed an association between a common magnetic resonance imaging (MRI) contrast agent and abnormalities on brain MRI, according to a new study published online in the journal Radiology. The new study raises the possibility that a toxic component of the contrast agent may remain in the body long after administration.

Brain MRI exams are often performed with a gadolinium-based contrast medium (Gd-CM). Gadolinium's paramagnetic properties make it useful for MRI, but the toxicity of the gadolinium ion means it must be chemically bonded with non-metal ions so that it can be carried through the kidneys and out of the body before the ion is released in tissue. Gd-CM is considered safe in patients with normal kidney function.

However, in recent years, clinicians in Japan noticed that patients with a history of multiple administrations of Gd-CM showed areas of high intensity, or hyperintensity, on MRI in two brain regions: the dentate nucleus (DN) and globus pallidus (GP). The precise clinical ramifications of hyperintensity are not known, but hyperintensity in the DN has been associated with multiple sclerosis, while hyperintensity of the GP is linked with hepatic dysfunction and several diseases.

To learn more, the researchers compared unenhanced T1-weighted MR images (T1WI) of 19 patients who had undergone six or more contrast-enhanced brain scans with 16 patients who had received six or fewer unenhanced scans. The hyperintensity of both the DN and the GP correlated with the number of Gd-CM administrations.

"Hyperintensity in the DN and GP on unenhanced MRI may be a consequence of the number of previous Gd-CM administrations," said lead author Tomonori Kanda, M.D., Ph.D., from Teikyo University School of Medicine in Tokyo and the Hyogo Cancer Center in Akashi, Japan. "Because gadolinium has a high signal intensity in the body, our data may suggest that the toxic gadolinium component remains in the body even in patients with normal renal function."

Dr. Kanda noted that because patients with multiple sclerosis tend to undergo numerous contrast-enhanced brain MRI scans, the hyperintensity of the DN seen in these patients may have more to do with the large cumulative gadolinium dose than the disease itself.

The mechanisms by which Gd-CM administration causes hyperintensity of the DN and GP remain unclear, Dr. Kanda said. Previous studies on animals and humans have shown that the ion can be retained in bone and tissue for several days or longer after administration.

"The hyperintensity of DN and GP on unenhanced T1WI may be due to gadolinium deposition in the brain independent of renal function, and the deposition may remain in the brain for a long time," Dr. Kanda suggested.

Dr. Kanda emphasized that there is currently no proof that gadolinium is responsible for hyperintensity on brain MRI. Further research based on autopsy specimens and animal experiments will be needed to clarify the relationship and determine if the patients with MRI hyperintensity in their brains have symptoms.

"Because patients who have multiple contrast material injections tend to have severe diseases, a slight symptom from the gadolinium ion may be obscured," Dr. Kanda said.

There are two types of Gd-CM , linear and macrocyclic, with distinct chemical compositions. Since the patients in the study received only the linear type, additional research is needed to see if the macrocyclic type can prevent MRI hyperintensity, according to Dr. Kanda.


'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert  

Related biology news :

1. Research reveals contrasting consequences of a warmer Earth
2. Bees attracted to contrasting colors when looking for nectar
3. First oral agent to quell invasive macular degeneration, restore lost vision
4. Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
5. Paints and coatings containing bactericidal agent nanoparticles combat marine fouling
6. Boston subway system to be used to test new sensors for biological agents
7. Project MICREAgents: Self-assembling smart microscopic reagents to pioneer pourable electronics
8. Novel non-antibiotic agents against MRSA and common strep infections
9. Production of FRP components without release agents
10. Developing second skin military fabric to repel chemical and biological agents
11. Preventive detention for oxidizing agents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Contrast agent linked with brain abnormalities on MRI
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... edition of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ... list for the third year in a row. Now in its 36th ... a set of quantitative metrics. In addition, BioPoint was also named to ... Bay State . ... ...
(Date:8/15/2017)... 2017 After spending the past two years building a ... collection, GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, ... adherence, and data collection vis a vis their members, under their ... launch of this offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... pharmaceutical and biotherapeutics development, announces the launch of the new NHS Agile ... gain kinetic binding data for a wide range of molecules, including small and ...
(Date:8/15/2017)... MA (PRWEB) , ... August 15, 2017 , ... Any ... need that has compromised these disciplines for more than half a century. Despite ... be counted. It is widely known that molecular tags developed for this purpose ...
Breaking Biology Technology: